Induction of antigenic immune tolerance to delay type 1 diabetes - challenges for clinical translation.
Journal
Current opinion in endocrinology, diabetes, and obesity
ISSN: 1752-2978
Titre abrégé: Curr Opin Endocrinol Diabetes Obes
Pays: England
ID NLM: 101308636
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
2
7
2022
medline:
12
7
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
Dissect the field of antigen-specific immunotherapy (ASIT) in type 1 diabetes (T1D), highlighting the major barriers currently blocking clinical translation. ASIT remains a promising approach in T1D to re-establish the proper balance in the immune system to avoid the autoimmune-mediated attack or destruction of beta-cells in the pancreas. Despite some encouraging preclinical results, ASIT has not yet successfully translated into clinical utility, predominantly due to the lack of validated and clinically useful biomarkers. To restore immune tolerance towards self-antigens, ASIT aims to establish a favourable balance between T effector cells and T regulatory cells. Whilst most ASITs, including systemic or oral administration of relevant antigens, have appeared safe in T1D, meaningful and durable preservation of functional beta-cell mass has not been proven clinically. Development, including clinical translation, remains negatively impacted by lack of predictive biomarkers with confirmed correlation between assay readout and clinical outcomes. To be able to address the high unmet medical need in T1D, we propose continued reinforced research to identify such biomarkers, as well efforts to ensure alignment in terms of trial design and conduct.
Identifiants
pubmed: 35776831
doi: 10.1097/MED.0000000000000742
pii: 01266029-202208000-00011
doi:
Substances chimiques
Autoantigens
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-385Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Richardson SJ, Pugliese A. 100 Years of insulin: pancreas pathology in type 1 diabetes: an evolving story. J Endocrinol 2021; 252:R41–R57.
Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010; 59:2087–2093.
Katsarou A, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers 2017; 3:17016.
Rawshani A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376:1407–1418.
Petrie JR, Sattar N. Excess cardiovascular risk in type 1 diabetes mellitus. Circulation 2019; 139:744–747.
McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021; 325:765–779.
Shams S, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol 2021; 12:680043.
Wang P, et al. Human beta cell regenerative drug therapy for diabetes: past achievements and future challenges. Front Endocrinol (Lausanne) 2021; 12:671946.
Xu G, et al. Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes. Nat Commun 2022; 13:1159.
Dejgaard TF, et al. Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obes Metab 2021; 23:2752–2762.
Dimitrios P, et al. Liraglutide as adjunct to insulin treatment in patients with type 1 diabetes: a systematic review and meta-analysis. Curr Diabetes Rev 2020; 16:313–326.
Kuhadiya ND, et al. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes. Diabetes Obes Metab 2019; 21:1054–1057.
Bender C, et al. The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes. Sci Adv 2020; 6:eabc5586.
Huffaker MF, et al. Approaches to establishing tolerance in immune mediated diseases. Front Immunol 2021; 12:744804.
Serra P, Santamaria P. Antigen-specific therapeutic approaches for autoimmunity. Nat Biotechnol 2019; 37:238–251.
Roep BO, Wheeler DCS, Peakman M. Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine. Lancet Diabet Endocrinol 2019; 7:65–74.
Hannelius U, Beam CA, Ludvigsson J. Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes. Diabetologia 2020; 63:2177–2181.
Orban T, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412–419.
Pagni PP, et al. Multicomponent plasmid protects mice from spontaneous autoimmune diabetes. Diabetes 2021; 71:157–169.
Coppieters KT, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209:51–60.
Pugliese A. Autoreactive T cells in type 1 diabetes. J Clin Invest 2017; 127:2881–2891.
Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015; 7:315ra189.
Bluestone JA, Tang Q. T(reg) cells-the next frontier of cell therapy. Science 2018; 362:154–155.
Volfson-Sedletsky V, et al. Emerging therapeutic strategies to restore regulatory T cell control of islet autoimmunity in type 1 diabetes. Front Immunol 2021; 12:635767.
Bonifacio E, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the pre-POINT randomized clinical trial. JAMA 2015; 313:1541–1549.
Ziegler AG, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open 2019; 9:e028578.
Smith EL, Peakman M. Peptide immunotherapy for type 1 diabetes—clinical advances. Front Immunol 2018; 9:392.
Krischer JP, et al. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 2017; 318:1891–1902.
Skyler JS, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial—type 1. Diabetes Care 2005; 28:1068–1076.
Bovy N, et al. OP09-52: long-term follow-up study of type 1 diabetes patients previously treated with IMCY-0098 or placebo in young adults with recent-onset type 1 diabetes. Diabetologia 2020; 63:1–485. (Abstract).
Wesley JD, et al. Peripheral autoreactive CD8 T-cell frequencies are too variable to be a reliable predictor of disease progression of human type 1 diabetes. Clin Transl Immunol 2021; 10:e1309.
Speake C, et al. Systematic assessment of immune marker variation in type 1 diabetes: a prospective longitudinal study. Front Immunol 2019; 10:2023.
Wiedeman AE, et al. Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression. J Clin Invest 2020; 130:480–490.
Tarbell KV, et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J Exp Med 2007; 204:191–201.
Carré A, et al. Presumption of guilt for T cells in type 1 diabetes: lead culprits or partners in crime depending on age of onset? Diabetologia 2021; 64:15–25.
Nakayama M, Michels AW. Using the T cell receptor as a biomarker in type 1 diabetes. Front Immunol 2021; 12:777788.
Hanna SJ, et al. Insights from single cell RNA sequencing into the immunology of type 1 diabetes – cell phenotypes and antigen specificity. Front Immunol 2021; 12:751701.
Fasolino M, et al. Single-cell multiomics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes. Nat Metab 2022; 4:284–299.
Rosenzwajg M, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia 2020; 63:1808–1821.
Dwyer CJ, et al. Promoting immune regulation in type 1 diabetes using low-dose interleukin-2. Curr Diabet Rep 2016; 16:46–146.
Graßhoff H, et al. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol 2021; 12:648408.
Jones CB, et al. Regulatory T cells control diabetes without compromising acute antiviral defense. Clin Immunol 2014; 153:298–307.
Spence A, et al. Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Proc Natl Acad Sci USA 2018; 115:5265–5270.
Mitchell AM, et al. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development. Proc Natl Acad Sci USA 2021; 118:
Loretelli C, et al. Cell therapy for type 1 diabetes. Expert Opin Biol Ther 2020; 20:887–897.
Raffin C, Vo LT, Bluestone JA. T(reg) cell-based therapies: challenges and perspectives. Nat Rev Immunol 2020; 20:158–172.
Herold KC, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62:3766–3774.
Herold KC, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019; 381:603–613.
Carré A, Mallone R. Making insulin and staying out of autoimmune trouble: the beta-cell conundrum. Front Immunol 2021; 12:639682.
James EA, et al. T-cell epitopes and neo-epitopes in type 1 diabetes: a comprehensive update and reappraisal. Diabetes 2020; 69:1311–1335.
Pagni PP, et al. Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes 2014; 63:2015–2025.
Bonifacio E, Achenbach P. Birth and coming of age of islet autoantibodies. Clin Exp Immunol 2019; 198:294–305.
von Herrath M, Bonifacio E. How benign autoimmunity becomes detrimental in type 1 diabetes. Proc Natl Acad Sci USA 2021; 118:
Critical Path Institute, C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative. Press release.
Zhang ZJ, et al. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 1991; 88:10252–10256.
Miller A, Lider O, Weiner HL. Antigen-driven bystander suppression after oral administration of antigens. J Exp Med 1991; 174:791–798.
Yeh WI, et al. Avidity and bystander suppressive capacity of human regulatory T cells expressing de novo autoreactive T-cell receptors in type 1 diabetes. Front Immunol 2017; 8:1313.
Jacobsen LM, et al. T cell receptor profiling in type 1 diabetes. Curr Diab Rep 2017; 17:118.
Chiou SH, et al. Global analysis of shared T cell specificities in human nonsmall cell lung cancer enables HLA inference and antigen discovery. Immunity 2021; 54:586.e8–602.e8.
Diggins KE, et al. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects. JCI Insight 2021; 6:
Gearty SV, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature 2022; 602:156–161.
Mathieu C, et al. Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia 2018; 61:2252–2258.
Yi L, Swensen AC, Qian WJ. Serum biomarkers for diagnosis and prediction of type 1 diabetes. Transl Res 2018; 201:13–25.
Wright JR Jr, Gale EAM. Winner's curse: the sad aftermath of the discovery of insulin. Diabet Med 2021; 38:e14677.
Richardson N, Wraith DC. Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity. Immunother Adv 2021; 1:ltab009.